The 2024 Advances in Cancer Immunotherapy™ series is supported, in part, through independent medical education grants from Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), and Novartis Pharmaceuticals Corporation. (Supporters as of Feb. 28, 2024)